Transplant Trial Watch

To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.

The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].

The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.

Click on each trial for more detail of findings and quality.


July 2016

Kidney transplantation

Long-Term Outcomes in Belatacept-Treated vs. Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results from BENEFIT-EXT, a Phase III Randomized Study.
Durrbach A, Pestana JM, et al. American Journal of Transplantation 2016 [record in progress].

Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial.
Origuen J, Lopez-Medrano F, et al. American Journal of Transplantation 2016 [record in progress].

Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.
Vincenti F, Silva HT, et al. American Journal of Transplantation 2015; 15(6): 1644-1653.

Effect of Statins on the Progression of Coronary Calcification in Kidney Transplant Recipients.
Yazbek DC, Carvalho AB, et al. PLoS ONE [Electronic Resource] 2016; 11(4): e0151797.

Steroid Avoidance or Withdrawal Regimens in Paediatric Kidney Transplantation: A Meta-Analysis of Randomised Controlled Trials.
Zhang H, Zheng Y, et al. PLoS ONE [Electronic Resource] 2016; 11(3): e0146523.

Liver transplantation

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.
Nguyen NH, Yee BE, et al. BMJ Open Gastroenterology 2016; 3(1): e000066.

Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M, Kaiser GM, et al. Clinical Transplantation 2016 Jun;30(6):741-8.

Lung transplantation

Everolimus versus mycophenolate mofetil de novo after lung transplantation - a prospective, randomized, open-label trial.
Strueber M, Warnecke G, et al. American journal of transplantation 2016; [record in progress].

Various organs

Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial.
Asberg A, Humar A, et al. Clinical Infectious Diseases 2016; 62(9): 1154-1160.

Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
Gullestad L, Eiskjaer H, et al. Transplant International 2016 Jul;29(7):819-29.